Market research
P8A.SG CORDLIFE GROUP LIMITED
Current ticker: P8A.SG
SG SGD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 31M
- P/E ratio
- Not available
- Analyst target
- 1.41
- Dividend yield
- Not available
- Beta
- 0.67
Profile
Instrument facts
- Exchange
- SG
- Currency
- SGD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- SG2E64980112
- Market cap
- 31M
- P/E ratio
- Not available
- Analyst target
- 1.41
- Dividend yield
- Not available
- Beta
- 0.67
About
About CORDLIFE GROUP LIMITED
Cordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, India, Malaysia, the Philippines, and internationally. It operates in two segments, Banking and Diagnostics. The Banking segment collects, processes, banks, and tests biological materials, such as cord blood, lining, and tissue samples. The Diagnostics segment offers diagnostic testing services, such as newborn genetic and metabolic screenings; pediatric vision and ear screenings; pediatric allergen test; and genetic talent test services. The company also provides corneal lenticule banking, and lifestyle genetic screening services for adults. In addition, it offers life sprouts, medical laboratory, marketing, and property investment services, as well as medical and pharmaceutical research and development and consulting services. Cordlife Group Limited was incorporated in 2001 and is based in Singapore.
Research context
CORDLIFE GROUP LIMITED appears in PyInvesting’s Singapore Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- SGD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the P8A.SG discussion.
5 years, 6 months ago
Cordlife Group Limited is currently in a long term uptrend where the price is trading 7.0% above its 200 day moving average.
From a valuation standpoint, the stock is 79.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.7.
Cordlife Group Limited's total revenue rose by 208.9% to $51M since the same quarter in the previous year.
Its net income has increased by 77.0% to $7M since the same quarter in the previous year.
Finally, its free cash flow grew by 172.3% to $4M since the same quarter in the previous year.
Based on the above factors, Cordlife Group Limited gets an overall score of 5/5.